In this commentary, we will analyze three studies emphasizing that wild-type IDH2 could be a potential therapeutic target for specific subsets of breast cancer [22] and that IDH2 inhibition promotes the differentiation of memory CD8+ T cells, thus enhancing the efficacy of cell-based immunotherapies such as chimeric antigen receptor (CAR) T cells [23,24]. Here, IDH2 is linked to breast carcinoma.